Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director · CEO and President | August 06, 2026 | August 10, 2026 |
| KERYX BIOPHARMACEUTICALS INCKERX · Entity 161794 | Director | June 09, 2017 | June 20, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date August 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,718,564 |
Reported balance
After 2026-08-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-06 · Exercise / conversion · Acquired 350,000 · Balance 3,718,564 F1: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2026 under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2033-01-31 | Direct | 525,000 |
Reported balance
After 2026-08-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-06 · Exercise / conversion · Disposed 350,000 · Balance 525,000 F2: The options were granted by the Issuer on January 31, 2023 and vest over four years: 25% of the options vested on January 31, 2024 with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. |
| Common StockSEC Table I · non-derivative | IndirectHeld by Dorothy Butler Revocable Trust November 20, 2007 | 159,928 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 159,928 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2026 under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
F2: The options were granted by the Issuer on January 31, 2023 and vest over four years: 25% of the options vested on January 31, 2024 with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
KERYX BIOPHARMACEUTICALS INC
Report date June 09, 2017 · Filed June 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2017-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-06-09 · Grant · Acquired 10,000 · Balance 20,000 F1: The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 9, 2018, June 9, 2019 and June 9, 2020. F2: Includes 16,666 shares of restricted stock. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.56 · Expires 2027-06-09 | Direct | 30,000 |
Reported balance
After 2017-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-09 · Grant · Acquired 30,000 · Balance 30,000 F3: The 30,000 stock options vest as to one-third on each of June 9, 2018, June 9, 2019 and June 9, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 9, 2018, June 9, 2019 and June 9, 2020.
F2: Includes 16,666 shares of restricted stock.
F3: The 30,000 stock options vest as to one-third on each of June 9, 2018, June 9, 2019 and June 9, 2020.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Zynerba Pharmaceuticals, Inc.
Report date October 10, 2023 · Filed October 11, 2023
Section 16 reporting ended · disclosed 2023-10-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-10-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-10-10 · Other · Disposed 32,941 · Balance 47,824 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). Row 2 · 2023-10-10 · Other · Disposed 47,824 · Balance 0 F3: This line item represents unvested restricted stock awards ("RSAs") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2023-10-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-10-10 · Disposition to issuer · Disposed 34,663 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2033-06-13 | Direct | 0 |
Reported balance
After 2023-10-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-10-10 · Disposition to issuer · Disposed 71,736 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2)
F2: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment").
F3: This line item represents unvested restricted stock awards ("RSAs") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5)
F5: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 10, 2026 20:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Exercise / conversionStock Option (Right to buy) · Derivative | 350,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001591467-26-000004 · primarydocument.xml · derivative · entry 3 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 350,000 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options were granted by the Issuer on January 31, 2023 and vest over four years: 25% of the options vested on January 31, 2024 with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Exercise / conversionCommon Stock | 350,000 | $0.63 | $220,500.00 |
DisclosureSEC source: 0001591467-26-000004 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,718,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2026 under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:55 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | PurchaseCommon Stock | 69,270 | $1.25 | $86,587.50 |
DisclosureSEC source: 0001591467-26-000003 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,367,064 F1 · shares: The reporting person's purchase of Akebia Therapeutics, Inc. ("Akebia") common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 69,270 shares, with the reporting person's sale of 341,305 shares of Akebia common stock at a price of $1.39 per share on February 2, 2026 pursuant to an automatic sell-to-cover instruction solely to cover applicable withholding taxes in connection with the vesting of the reporting person's RSUs granted on January 31, 2023, 2024 and 2025. The reporting person has paid Akebia, upon settlement of the sale, $9,664.60 representing the full amount of the profit realized in connection with the short-swing transaction. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 83,689 | $1.39 | $116,327.71 |
DisclosureSEC source: 0001591467-26-000002 · primarydocument.xml · nonDerivative · entry 5 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,297,794 F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. F6 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's performance stock units granted on January 31, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 175,250 | $1.41 | $247,102.50 |
DisclosureSEC source: 0001591467-26-000002 · primarydocument.xml · nonDerivative · entry 4 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,381,483 F5 · shares: As reported in February 2025, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2023 Stock Incentive Plan, as amended. Each PSU right represents a contingent right to receive one share of the Issuer's common stock. One-half of the total number of shares of common stock underlying the PSUs vests on the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $3.50 over a 30-day trading period (the "Stock Price Hurdle 1 Performance Condition"), subject to the reporting persons continuous employment through the applicable vesting date. In July2025, the Compensation Committee certified that the Stock Price Hurdle 1 Performance Condition was met during the performance period and therefore one-half of the PSUs vested on January 31, 2026. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 114,891 | $1.39 | $159,698.49 |
DisclosureSEC source: 0001591467-26-000002 · primarydocument.xml · nonDerivative · entry 3 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,206,233 F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 96,065 | $1.39 | $133,530.35 |
DisclosureSEC source: 0001591467-26-000002 · primarydocument.xml · nonDerivative · entry 2 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,321,124 F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 46,660 | $1.39 | $64,857.40 |
DisclosureSEC source: 0001591467-26-000002 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,417,189 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023. F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:35 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 1,115,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001591467-26-000001 · primarydocument.xml · derivative · entry 3 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,115,000 Underlying: Common Stock · 1,115,000 shares Expires 2036-01-30 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:35 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 743,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001591467-26-000001 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,463,849 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 159,928 shares previously held by John Butler 2019 GRAT, and 1,500 shares of the Issuer's common stock purchased on June 30, 2025 and 1,500 shares of the Issuer's common stock purchased on December 31, 2025, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:05 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 46,409 | $1.83 | $84,928.47 |
DisclosureSEC source: 0001562180-25-001998 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,557,921 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2023. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:54 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 97,982 | $2.10 | $205,762.20 |
DisclosureSEC source: 0001562180-25-000917 · primarydocument.xml · nonDerivative · entry 3 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,604,330 F3 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2023. F5 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:54 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 46,268 | $2.10 | $97,162.80 |
DisclosureSEC source: 0001562180-25-000917 · primarydocument.xml · nonDerivative · entry 2 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,702,312 F3 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2023. F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:54 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 1,051,400 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001562180-25-000917 · primarydocument.xml · derivative · entry 9 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,051,400 Underlying: Common Stock · 1,051,400 shares Expires 2035-01-31 F7 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:54 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantPerformance Stock Units · Derivative | 350,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000917 · primarydocument.xml · derivative · entry 8 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 350,500 Underlying: Common Stock · 350,500 shares Expires 2027-01-31 F6 · derivative.exercise_price: Each Performance Stock Unit ("PSU") right represents a contingent right to receive one share of the Issuer's common stock. One-half of the total number of shares of common stock underlying the PSUs shall vest on each of (a) the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $3.50 over a 30-day trading period, and (b) the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $5.00 for over a 30-day trading period, subject to the reporting person's continued service with the Issuer through the applicable vesting date. F6 · derivative.exercise_date: Each Performance Stock Unit ("PSU") right represents a contingent right to receive one share of the Issuer's common stock. One-half of the total number of shares of common stock underlying the PSUs shall vest on each of (a) the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $3.50 over a 30-day trading period, and (b) the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $5.00 for over a 30-day trading period, subject to the reporting person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:54 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 701,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000917 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,748,580 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2024 and 1,500 shares of the Issuer's common stock purchased on December 31, 2024, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:47 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 46,570 | $1.58 | $73,580.60 |
DisclosureSEC source: 0001562180-24-002021 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,044,580 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:00 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 37,733 | $1.52 | $57,354.16 |
DisclosureSEC source: 0001562180-24-001992 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,091,150 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 46,489 | $1.68 | $78,101.52 |
DisclosureSEC source: 0001562180-24-000971 · primarydocument.xml · nonDerivative · entry 2 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,128,883 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31,2023. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 905,200 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001562180-24-000971 · primarydocument.xml · derivative · entry 7 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 905,200 Underlying: Common Stock · 905,200 shares Expires 2034-01-31 F4 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 603,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000971 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,175,372 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 13:58 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | Disposition to issuerStock Option (Right to Buy) · Derivative | 71,736 | Not disclosed Strike: $0.35 | Not disclosed |
DisclosureSEC source: 0001140361-23-047727 · form4.xml · derivative · entry 4 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,736 shares Expires 2033-06-13 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · price: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · derivative.exercise_date: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 13:58 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | Disposition to issuerStock Option (Right to Buy) · Derivative | 34,663 | Not disclosed Strike: $1.01 | Not disclosed |
DisclosureSEC source: 0001140361-23-047727 · form4.xml · derivative · entry 3 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,663 shares Expires 2032-06-14 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · price: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · derivative.exercise_date: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 13:58 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | OtherCommon Stock | 47,824 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-047727 · form4.xml · nonDerivative · entry 2 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · shares: This line item represents unvested restricted stock awards ("RSAs") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest. F3 · price: This line item represents unvested restricted stock awards ("RSAs") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 13:58 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | OtherCommon Stock | 32,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-047727 · form4.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,824 F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2 · price: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:28 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | SaleCommon Stock | 115 | $0.35 | $40.03 |
DisclosureSEC source: 0001062993-23-013664 · form4.xml · nonDerivative · entry 2 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,765 F2 · shares: This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees and taxes in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:28 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 71,736 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001062993-23-013664 · form4.xml · derivative · entry 3 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,736 Underlying: Common Stock · 71,736 shares Expires 2033-06-13 F3 · derivative.exercise_date: The option vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:28 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 47,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-013664 · form4.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,880 F1 · shares: The restricted stock award vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 13:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,370 | $0.88 | $5,589.68 |
DisclosureSEC source: 0001562180-23-002201 · primarydocument.xml · nonDerivative · entry 3 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,568,872 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 13:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 47,239 | $0.88 | $41,452.22 |
DisclosureSEC source: 0001562180-23-002201 · primarydocument.xml · nonDerivative · entry 2 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575,242 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 13:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 38,259 | $0.88 | $33,572.27 |
DisclosureSEC source: 0001562180-23-002201 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,622,481 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:07 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 38,632 | $0.81 | $31,415.54 |
DisclosureSEC source: 0001562180-23-002041 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,660,740 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:15 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 875,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001562180-23-000832 · primarydocument.xml · derivative · entry 7 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,000 Underlying: Common Stock · 875,000 shares Expires 2033-01-31 F4 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:15 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Appreciation Right · Derivative | 635,313 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001562180-23-000832 · primarydocument.xml · derivative · entry 6 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 635,313 Underlying: Common Stock · 635,313 shares Expires 2033-01-31 F3 · derivative.exercise_date: The stock appreciation rights ("SARs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The SARs will vest over four years: 25% of the SARs will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:15 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 293,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000832 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,699,372 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2022 and 1,500 shares of the Issuer's common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 01:48 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 34,663 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001062993-22-015037 · form4.xml · derivative · entry 3 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,663 Underlying: Common Stock · 34,663 shares Expires 2032-06-14 F3 · derivative.exercise_date: The option vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 01:48 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | SaleCommon Stock | 53 | $1.01 | $53.53 |
DisclosureSEC source: 0001062993-22-015037 · form4.xml · nonDerivative · entry 2 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,056 F2 · shares: This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees and taxes in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 01:48 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 23,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-015037 · form4.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,109 F1 · shares: The restricted stock award vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:25 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 4,131 | $2.17 | $8,967.16 |
DisclosureSEC source: 0001562180-22-002166 · primarydocument.xml · nonDerivative · entry 5 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,403,247 F6 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:25 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 25,031 | $2.17 | $54,334.79 |
DisclosureSEC source: 0001562180-22-002166 · primarydocument.xml · nonDerivative · entry 4 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,378 F5 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:25 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 24,811 | $2.17 | $53,857.24 |
DisclosureSEC source: 0001562180-22-002166 · primarydocument.xml · nonDerivative · entry 3 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,432,409 F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:25 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 739,700 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001562180-22-002166 · primarydocument.xml · derivative · entry 10 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739,700 Underlying: Common Stock · 739,700 shares Expires 2032-02-28 F7 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:25 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 293,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-002166 · primarydocument.xml · nonDerivative · entry 2 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,457,220 F3 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:25 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 25,053 | $2.15 | $53,984.20 |
DisclosureSEC source: 0001562180-22-002166 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,164,095 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. F2 · balance_after: Includes: (i) the 1,248 shares of common stock that were described in the amendment on Form 4/A filed by the reporting person with the SEC on February 18, 2022, (ii) 1,500 shares of the Issuer's common stock purchased on each of June 30, 2021 and December 31, 2021, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan, and (iii) 32,747 shares of common stock that represent a change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:28 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001192482-21-000646 · edgar.xml · derivative · entry 2 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-08-03 F2 · derivative.exercise_date: The option vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:28 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000646 · edgar.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: The restricted stock award vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 00:32 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 4,109 | $3.40 | $13,970.60 |
DisclosureSEC source: 0001562180-21-002540 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,152,153 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:17 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 39,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-002354 · primarydocument.xml · nonDerivative · entry 1 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,156,262 F1 · shares: As previously disclosed, in February 2020, the Reporting Person was granted performance-based restricted stock unit awards ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest in connection with the achievement of specified commercial and regulatory milestones. On February 25, 2021, the Company reported its financial results for the year ended December 31, 2020. Subsequently, in accordance with the terms of the grant, the Issuer's Compensation Committee certified the achievement of a commercial milestone and, as a result, one third of the reported PSUs will vest on each of March 31, 2021, February 28, 2022 and February 28, 2023, subject to the Reporting Person's continued service with the Issuer on each vesting date. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 24,674 | $3.40 | $83,795.37 |
DisclosureSEC source: 0001562180-21-001787 · primarydocument.xml · nonDerivative · entry 3 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,116,742 F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 25,316 | $3.40 | $85,975.67 |
DisclosureSEC source: 0001562180-21-001787 · primarydocument.xml · nonDerivative · entry 2 Butler John P. · CIK 0001591467 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141,416 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.